Menu
Back to Journals » Drug, Healthcare and Patient Safety » Volume 11
Safety and tolerability of macitentan in the management of pulmonary arterial hypertension: an update
Authors Wong AK, Channick RN
Received 30 January 2019
Accepted for publication 12 July 2019
Published 3 September 2019 Volume 2019:11 Pages 71—85
DOI https://doi.org/10.2147/DHPS.S173050
Checked for plagiarism Yes
Review by Single-blind
Peer reviewer comments 3
Editor who approved publication: Dr Rajender R Aparasu
Alexandra K Wong,1 Richard N Channick2
1Division of Pulmonary and Critical Care, Massachusetts General Hospital, Boston, MA 02114, USA; 2Division of Pulmonary and Critical Care, University of California Los Angeles Medical Center, Los Angeles, CA 90095, USA
Correspondence: Alexandra K Wong
Division of Pulmonary and Critical Care, Massachusetts General Hospital, 55 Fruit Street, Boston, MA 02114, USA
Tel +1 617 724 9674
Fax +1 617 726 6878
Email akunin1@partners.org
Abstract: Macitentan is a medication in the endothelin receptor antagonist class, approved for treatment of pulmonary arterial hypertension in 2013 based on the results of the pivotal SERAPHIN Trial (Study with an Endothelin Receptor Antagonist in Pulmonary arterial Hypertension to Improve cliNical outcome). Macitentan was shown in initial trials to reduce the likelihood of a morbidity/mortality event. Real-world use of this medication additionally reveals a reduced risk of hospitalizations related to pulmonary arterial hypertension, improved health-related quality of life scores, potential clinical utility in other conditions (such as chronic thromboembolic pulmonary hypertension and pulmonary hypertension related to congenital heart disease), and has a similar safety profile as demonstrated in initial trials.
Keywords: macitentan, pulmonary arterial hypertension, safety, tolerability, efficacy
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License.
By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.